— Generic approved as part of combination regimens for active and latent pulmonary TB
June 23, 2026
• 1 min read
The FDA approved the first generic version of rifapentine (Priftin) to treat active pulmonary tuberculosis (TB) in adolescents and adults, as well as latent TB infection in patients as young as 2 years.
The generic rifamycin-class oral antibiotic is approved only in combination with one or more anti-tuberculosis drugs to treat active pulmonary TB caused by Mycobacterium tuberculosis in patients ages 12 years or older with susceptible isolates. In latent TB cases caused by M. tuberculosis, generic rifapentine is approved in combination with isoniazid to treat patients ages 2 years or older who are at high risk of progressing to TB disease.
